ClinicalTrials.gg
CompletedNCT01128322Updated Apr 26, 2011

CKD-828 Primary Hypertension Trial(Dose-selection)

A Phase 2 interventional study of S-Amlodipine, Telmisartan and S-Amlodipine in Hypertension, sponsored by Chong Kun Dang Pharmaceutical. Completed at 26 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-26.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Chong Kun Dang Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical — 2 open to participants now, 2 under way, 1 of them phase 3. Essential Hypertension · Chong Kun Dang Pharmaceutical.

Planned enrollment
2nd of 17
430 · median 169
Started
2010
with 1 other
Phase 2
2 of 18
none open now
Registered
1st of 18
by date

Among the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 2 in phase 2, and was the 1st registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Essential Hypertension by Chong Kun Dang Pharmaceutical, or all of them as a file.
02

Study summary

The aim of this trial is to determine the best dose combination of S-Amlodipine and Telmisartan as compared to monotherapy by assessing the blood pressure lowering effects of a once daily regimen of various combinations of S-Amlodipine and Telmisartan, compared to their monotherapy components and placebo, in patients with stage I or II essential hypertension(a mean seated cuff diastolic blood pressure >=95 and \<=115 mmHg).

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • CKD-828
  • Hypertension
  • Primary Hypertension
  • S-Amlodipine
  • Telmisartan
  • Amlodipine
  • Factorial
  • Phase 2
04

In context

Essential Hypertension Reclassified

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

This study's planned enrollment of 430 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Chong Kun Dang Pharmaceutical is the lead sponsor of 299 studies on the registry; 14 are open to participants now.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18 years or older
  • stage I or II hypertension defined as: a mean seated cuff diastolic blood pressure >=95 and \<=115 mmHg
  • ability to provide written

Exclusion criteria

Exclusion Criteria:

  • severe hypertension defined as: a mean seated cuff diastolic blood pressure >=116mmHg or a mean seated cuff systolic blood pressure >=200mmHg
  • known or suspected secondary hypertension(ex. aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma)
  • has severe heart disease(Heart failure functional class 3, 4), unstable angina or myocardial infarction, arrhythmia within the past three months
  • has cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months
  • Type I Diabets Mellitus, Type II Diabetes Mellitus with poor glucose control as defined by fasting glucosylated () > 8%
  • known severe or malignant retinopathy
  • hepatic or renal dysfunction as defined by the following laboratory parameters: /ALT > UNL X 2, serum creatinine > UNL X 1.5
  • acute or chronic inflammatory status need to treatment
  • need to additional antihypertensive drugs during the study
  • need to concomitant medications known to affect blood pressure during the study
  • history of angioedema related to ACE inhibitors or Angiotensin II Receptor Blockers
  • known related to either study drug
  • history of drug or alcohol dependency
  • any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of products(ex. gastrointestinal tract surgery such as gastrectomy, gastroenterostomy or bypass, active inflammatory bowel syndrome within 12 months prior to screening, currently active gatritis, ulcers of gastrointetinal/rectal bleeding, impaired pancreatic fuction such as pancreatitis,obstructions of the urinary tract or difficulty in voiding)
  • cannot swallow investigational products
  • administration of other study drugs within 4 weeks prior to randomization
  • premenopausal women(last menstration \< 1year) not using adequte , pregnant or breast-feeding
  • history of including leukemia and lymphoma within the past 5 years
  • in investigator's judgment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
430 participants (estimated)

Study arms

  • Experimental
    S-Amlodipine 2.5mg + Telmisartan 40mg

    Drug: S-Amlodipine, Telmisartan

  • Experimental
    S-Amlodipine 2.5mg + Telmisartan 80mg

    Drug: S-Amlodipine, Telmisartan

  • Experimental
    S-Amlodipine 5mg + Telmisartan 40mg

    Drug: S-Amlodipine, Telmisartan

  • Experimental
    S-Amlodipine 5mg + Telmisartan 80mg

    Drug: S-Amlodipine, Telmisartan

  • Active comparator
    S-Amlodipine 2.5mg

    Drug: S-Amlodipine

  • Active comparator
    S-Amlodipine 5mg

    Drug: S-Amlodipine

  • Active comparator
    Telmisartan 40mg

    Drug: Telmisartan

  • Active comparator
    Telmisartan 80mg

    Drug: Telmisartan

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Sitting Diastolic Blood Pressure(MSDBP)

    Time frame: After 8 weeks of treatment

Secondary outcomes

  1. Mean Sitting Diastolic Blood Pressure(MSDBP)

    Time frame: After 4 weeks of treatment

  2. Mean Sitting Systolic Blood Pressure(MSSBP)

    Time frame: After 4 weeks and 8 weeks of treatment

  3. Response rate

    Reduction of SBP ≥ 20mmHg, DBP ≥ 10mmHg

    Time frame: After 4 weeks and 8 weeks of treatment

  4. Control rate

    Reduction SBP \< 140mmHg, DBP \< 90mmHg

    Time frame: After 4 weeks and 8 weeks of treatment

08

Study locations

26 sites
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
  • Soonchunhyang University Hospital in Bucheon
    Bucheon, Korea, Republic of
  • Kosin University Gospel Hospital
    Busan, Korea, Republic of
  • Chungbuk National Uiversity Hospital
    Cheongju, Korea, Republic of
  • Daegu Catholic University Medical Center
    Daegu, Korea, Republic of
  • Keimyung University Dongsan Medical Center
    Daegu, Korea, Republic of
  • DonGuk University International Hospital
    Goyang, Korea, Republic of
  • National Health Insurance Corporation Ilsan Hospital
    Goyang, Korea, Republic of
  • Chonnam National University Hospital
    Gwangju, Korea, Republic of
  • Gachon University Gil Medical Center
    Inchon, Korea, Republic of
  • Chonbuk National University Hospital
    Jeonju, Korea, Republic of
  • Pusan National University Hospital
    Pusan, Korea, Republic of
  • Seoul National University Bundang Hospital
    Seongnam, Korea, Republic of
  • Ewha Womans University Hospital
    Seoul, Korea, Republic of
  • Gangnam Severance Hospital
    Seoul, Korea, Republic of
  • Kandong Sacred Heart Hospital
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
  • Kyung Hee University Medical Center
    Seoul, Korea, Republic of
  • Seoul St. Mary's Hospital, The catholic University of Korea
    Seoul, Korea, Republic of
  • Severance Hospital
    Seoul, Korea, Republic of
  • SMG-SNU Boramae Medical Center
    Seoul, Korea, Republic of
  • Soon Chun Hyang University Hospital
    Seoul, Korea, Republic of
  • St. Paul's Hospital, The catholic University of Korea
    Seoul, Korea, Republic of
  • Ajou University Hospital
    Suwon, Korea, Republic of
  • Uijeongbu St. Mary's Hospital, The catholic University of Korea
    Uijeongbu, Korea, Republic of
  • Wonju Christian Hospital
    Wonju, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
May 21, 2010
Start
Jul 2010
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Last update
Apr 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01128322
First posted
May 21, 2010
Start date
Jul 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Apr 26, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levamlodipine · Telmisartan

Start the discussion